David A. Siegel Stoke Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 19,700 shares of STOK stock, worth $241,128. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,700Holding current value
$241,128% of portfolio
0.0%Shares
11 transactions
Others Institutions Holding STOK
# of Institutions
117Shares Held
55.6MCall Options Held
14KPut Options Held
8.8K-
Skorpios Trust10.8MShares$133 Million99.89% of portfolio
-
Black Rock Inc. New York, NY5.41MShares$66.2 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.72MShares$57.8 Million4.16% of portfolio
-
Baker Bros. Advisors LP New York, NY4.37MShares$53.5 Million0.78% of portfolio
-
Rtw Investments, LP New York, NY4.22MShares$51.7 Million0.95% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $482M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...